ViewPoints Interview: Biogen’s Monica Mann Shares Insight on Plegridy to Treat Multiple Sclerosis
Shots: The P-III HELP (Hereditary Angioedema Long-term Prophylaxis) study involves assessing of Takhzyro (300/150 mg, SC) (lanadelumab) vs PBO in 125 patients with HAE attacks for 26 weeks aged 12 years and older The P-III HELP result: reduction in mean monthly attack rate 80.1% ; fewer severe attacks (7.4% vs. 22%); HAE attack-free (48.1% vs […]Read More
